Landos Biopharma Inc expected to post a loss of 33cents a share - Earnings Preview

Landos Biopharma

22/03/2022 11:15

* Landos Biopharma Inc  LABP.OQ   LABP.O  is expected
to show no
change in quarterly revenue when it reports  results on March
24. 
    * ​Refinitiv's mean analyst estimate for Landos Biopharma
Inc is
for a loss of 33 cents per share. For the same quarter last
year, the company reported a loss of 91 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Landos
Biopharma
Inc is $26.75​, above​ its last closing price of $1.70. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.44       -0.44      -0.32     Beat    27
 Jun. 30 2021  0.04        -0.14      0.12      Beat    185.7
 Mar. 31 2021  -0.39       -0.37      -0.38     Missed  -1.3​
 Dec. 31 2020  -0.69       -0.69      -0.91     Missed  -32.5
 ​​                                                     
                                                        ​
 This summary was machine generated March 22 at 11:15 GMT.  All
figures in US dollars  unless otherwise stated